arrow_back Back to App

Increased Diversity in Clinical Trials for Drugs and Medical Devices

This act aims to boost participation of diverse demographic groups (age, sex, race, ethnicity) in clinical trials for drugs and medical devices. Companies will need to submit diversity plans and report on their progress, ensuring that medical products are safe and effective for everyone. Citizens can expect medical products to be better tailored to the needs of a diverse population.
Key points
Drug and device companies must plan and report on how they include diverse age, sex, race, and ethnic groups in their clinical trials.
If companies fail to meet diversity targets, the FDA can require additional studies after product approval to gather missing data.
The act mandates public meetings and reports on progress in increasing trial diversity and using real-world evidence.
Financial support for community health centers to participate in clinical trials and reach underrepresented communities.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_6584
Sponsor: Rep. Eshoo, Anna G. [D-CA-18]
Process start date: 2022-02-03
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

DEPICT Act

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_6584.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-02-03.

What are the main provisions?

Key points include:

  • Drug and device companies must plan and report on how they include diverse age, sex, race, and ethnic groups in their clinical trials.
  • If companies fail to meet diversity targets, the FDA can require additional studies after product approval to gather missing data.
  • The act mandates public meetings and reports on progress in increasing trial diversity and using real-world evidence.
  • Financial support for community health centers to participate in clinical trials and reach underrepresented communities.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Eshoo, Anna G. [D-CA-18].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health